Kaleido Biosciences, Inc. (KLDO)

Market Cap	4.26K
Revenue (ttm)	1.10M +13.2%
Net Income	-90.29M
EPS	-2.16
Shares Out	42.62M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	150
Average Volume	1,170
Open	0.0001
Previous Close	0.0001
Day's Range	0.0001 - 0.0001
52-Week Range	n/a
Beta	41.54
RSI	48.19
Earnings Date	n/a

About Kaleido Biosciences

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of ulcerative colitis, psoriasis, atopic immune disease, chronic obstructive pulmonary disease pathogens, and immuno-oncology. The company has collaboration agreements with Institute Gustave Rous...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 76
• Stock Exchange: OTCMKTS
• Ticker Symbol: KLDO

Financial Performance

In 2021, Kaleido Biosciences's revenue was $1.10 million, an increase of 13.23% compared to the previous year's $975,000. Losses were -$90.29 million, 10.6% more than in 2020.